AstraZeneca (LON:AZN) Given Overweight Rating at JPMorgan Chase & Co.

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reiterated by investment analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Thursday,Digital Look reports. They currently have a £140 ($182.24) price objective on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 43.96% from the stock’s previous close.

Several other research analysts have also commented on AZN. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Thursday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a £110 ($143.19) price objective on shares of AstraZeneca in a report on Tuesday, September 3rd. Finally, Berenberg Bank reissued a “buy” rating and issued a £150 ($195.26) target price on shares of AstraZeneca in a research note on Monday, September 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of £104.12 ($135.54).

AstraZeneca Stock Performance

AZN traded down GBX 197 ($2.56) on Thursday, hitting GBX 9,725 ($126.59). The company’s stock had a trading volume of 7,962,363 shares, compared to its average volume of 3,954,094. The company’s 50 day simple moving average is £120.21 and its 200-day simple moving average is £121.65. The firm has a market cap of £150.74 billion, a P/E ratio of 3,087.30, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. AstraZeneca has a 12 month low of GBX 9,461 ($123.16) and a 12 month high of £133.88 ($174.28).

Insider Activity

In related news, insider Michel Demare acquired 2,000 shares of AstraZeneca stock in a transaction that occurred on Friday, September 13th. The stock was bought at an average price of GBX 118 ($1.54) per share, with a total value of £2,360 ($3,072.12). Insiders own 0.04% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.